Notice

Error
  • Error loading feed data
  • Error loading feed data
  • Error loading feed data

PRCSG News

Abstracts  / Posters / Presentations

 

 

ACR Convergence 2020

November 5 - 9, 2020

Virtual meeting

 

JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years With Polyarticular-Course JIA Treated With SC Abatacept. Ruperto N, Brunner H, Berman A, Avila-Zapata F, Horneff G, Alessio M, Becker M, Belot A, Burgos-Vargas R, Boteanu A, Goldenstein-Schainbert C, Scheibel I, Terreri M, Zemel L, Wong R, Askelson M, Nys M, Martini A, Lovell D.

 

Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry. Lovell DJ, Brunner HI, Tzaribachev N, Morgan E, Simonini G, Griffin TA, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevica V, Tarvin S, Trachana M, Huber A, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou TD.

 

Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry. Lovell DJ, Tzaribachev N, Morgan E, Simonini G, Griffin T, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevicha V, Tarvin S, Trachana M, Huber A, Kietz D, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou T, Wong R, Martini A, Brunner H, Ruperto N.

 

Tofacitinib for the treatment of patients with juvenile idiopathic arthritis: an interim analysis of data up to 5.5 years from an open-label, long-term extension study. Brunner HI, Akikusa J, Al-Abadi E, Bohnsack J, Lucica Boteanu A, Chedeville G, Cuttica R, de La Pena W, Jung L, Kasapcopur O, Kobusinska K, Schulert G, Neiva C, Rivas-Chacon R, Rizo Rodreguez JC, Vazques-Del Mercado M, Wagner-Weiner L, Weiss JE, Wouters C, Suehiro RM, Posner H, Wouters A, Kanik KS, Luo Z, Martini A, Lovell DJ, Ruperto N. 

  ************************************************************************************************************************

 

September 2020 - FDA Approves Simponi ARIA (IV golimumab) for the Treatment of polyarticular course juvenile idiopathic arthritis (pcJIA). News release

 

September 2020 - FDA Approves XELJANZ/XELJANZ (tofacitinib) Oral formulation for the Treatment of polyarticular course juvenile idiopathic arthritis (pcJIA). Press release

 

August 2020 - Canakinumab improves systemic juvenile idiopathic arthritis regardless of fever Healio

 

New Publications: 

Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, Schneider R, Wulffraat NM, Chasnyk V, Tirosh I, Kallinich T, Kuemmerle-Deschner J, Wouters C, Lauwerys B, Nikishina I, Trachana M, Vougiouka O, Martini A, Lovell DJ, Levy J, Vritzali E, Ruperto N for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.

 

Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis with and without Fever at Baseline: Results from an Open-Label, Active-Treatment Extension Study.

Arthritis Rheumatol. 2020 Jul 10. doi: 10.1002/art.41436. Epub ahead of print. PMID: 32648697.